PF-Atlas › Clinical Trials › NCT05415137
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Efzofitimod 3 mg/kg · Phase 3
Registry ID
NCT05415137
Phase
Phase 3
Status
Completed
Drug / intervention
Efzofitimod 3 mg/kg
Sponsor
aTyr Pharma, Inc.
Start
2022-09-15
Enrollment
268
Locations
91
About this trial
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05415137 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.